Labiotech ١٥ مايو ٢٠٢٦ Freeze variability, not progress: strengthen your cell therapy supply chain from the start
Labiotech ٧ مايو ٢٠٢٦ The rise of trispecific antibodies: Biopharma’s next big bet after bispecifics
Labiotech ٢٩ أبريل ٢٠٢٦ When ADCs meet targeted protein degraders: The emerging field of degrader-antibody conjugates